Att 2 - 60 day FRN

47072

Federal Register / Vol. 77, No. 152 / Tuesday, August 7, 2012 / Notices

mstockstill on DSK4VPTVN1PROD with NOTICES

circumstances in which the three-part
test heretofore utilized under the
Statement is not met, such as where the
alleged antitrust violation is not clear or
where other remedies would be
sufficient to address the violation. I
have significant concerns about sending
such a signal and seeking disgorgement
in such situations.
In withdrawing the Policy Statement,
the majority makes the vague assertion
that ‘‘[i]t has been our experience that
the Policy Statement has chilled the
pursuit of monetary remedies in the
years since the statement’s issuance.’’ 5
I have not been presented with any
evidence that the Policy Statement has
inappropriately constrained the
Commission in the nine years it has
been in effect. This begs the questions
why the agency needs to rescind the
Policy Statement now and why it
should not perhaps be revised rather
than rescinded altogether.
The guidance in the Policy Statement
will be replaced by this view: ‘‘[T]he
Commission withdraws the Policy
Statement and will rely instead upon
existing law, which provides sufficient
guidance on the use of monetary
equitable remedies.’’ 6 This position
could be used to justify a decision to
refrain from issuing any guidance
whatsoever about how this agency will
interpret and exercise its statutory
authority on any issue. It also runs
counter to the goal of transparency,
which is an important factor in ensuring
ongoing support for the agency’s
mission and activities. In essence, we
are moving from clear guidance on
disgorgement to virtually no guidance
on this important policy issue.
Finally, I am troubled by the seeming
lack of deliberation that has
accompanied the withdrawal of the
Policy Statement. Notably, the
Commission sought public comment on
a draft of the Policy Statement before it
was adopted. That public comment
process was not pursued in connection
with the withdrawal of the statement. I
believe there should have been more
internal deliberation and likely public
input before the Commission withdrew
a policy statement that appears to have
5 Fed. Trade Comm’n, Withdrawal of the
Commission’s Policy Statement on Monetary
Equitable Remedies in Competition Cases, at 2 (July
31, 2012).
6 Id. at 1.

VerDate Mar<15>2010

16:52 Aug 06, 2012

Jkt 226001

served this agency well over the past
nine years.
[FR Doc. 2012–19185 Filed 8–6–12; 8:45 am]
BILLING CODE 6750–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–12–0128]

Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–7570 and
send comments to Kimberly S. Lane,
1600 Clifton Road, MS–D74, Atlanta,
GA 30333 or send an email to
[email protected].
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.
Proposed Project
Congenital Syphilis (CS) Case
investigation and Report Form
(CDC73.126), (OMB) No.0920–0128,
Expiration (03/31/2013)—Revision—
Division of STD Prevention (DSTDP),
National Center for HIV, Viral Hepatitis,
STD and TB Prevention (NCHHSTP),
Centers for Disease Control and
Prevention (CDC).

PO 00000

Frm 00045

Fmt 4703

Sfmt 4703

Background and Brief Description
Congenital syphilis (CS) is an
important sentinel health event that
marks potential problems in both
prenatal care and syphilis prevention
programs. Congenital syphilis (CS) is
nearly 100% preventable by early
detection and treatment of syphilis in
pregnant women before or during
pregnancy.
Reducing congenital syphilis is a
national objective in the U.S.
Department of Health and Human
Services report entitled, ‘‘Healthy
People 2020’’.
The CDC continues to collect and
report information on congenital
syphilis morbidity as part of its ongoing
Sexually Transmitted Disease (STD)
surveillance efforts. A reporting form for
congenital syphilis (CDC Form 73.126)
was initiated in 1983 to improve
detection, case management, and
treatment of congenital syphilis cases.
Continued data collection will assist in
identifying needs for congenital syphilis
prevention efforts nationwide.
The current CS reporting form was
revised and approved by OMB in 2009
to collect information based on the
surveillance case definition and removal
of Reporting city information. It is being
used by all health jurisdictions
reporting CS to CDC as part of the
National Notifiable Diseases
Surveillance. For the new approval
period, CDC requests elimination of the
field ‘‘Did the infant/child have an IgMspecific treponemal test?’’ This data
element is no longer required because
treponemal IgM technologies, for the
purpose of identifying CS in an infant,
are highly insensitive. The following
fields have been added: ‘‘Mothers
obstetric history’’, ‘‘Did mother have
treponemal test result: If so, when was
the test performed?’’ ‘‘What stage of
syphilis did mother have?’’, ‘‘Date of
Mother’s treatment’’, ‘‘What was
mother’s treatment?’’ ‘‘Congenital
Syphilis Case Classification—
Presumptive has been replaced with
probable,’’ as there is no case definition
for presumptive congenital syphilis.
This information collection is
authorized under Sections 301 and 318
of the Public Health Service Act (42
U.S.C. 241 and 247c).
The congenital syphilis data will
continue to be used to develop
intervention strategies and to evaluate
ongoing control efforts. There is no cost
to respondents other than their time.

E:\FR\FM\07AUN1.SGM

07AUN1

47073

Federal Register / Vol. 77, No. 152 / Tuesday, August 7, 2012 / Notices
ESTIMATE OF ANNUALIZED BURDEN TABLE
Average
Burden per
Response
(in hours)

Total annual
burden
(in hours)

Form name

State Health Departments ................

Congenital Syphilis (CS) Case Investigation and Report.
Congenital Syphilis (CS) Case Investigation and Report.
Congenital Syphilis (CS) Case Investigation and Report.

10

11

20/60

37

3

11

20/60

11

4

11

20/60

15

...........................................................

17

........................

........................

63

Territorial Health Agencies ...............
City and county health departments
Total ...........................................

Dated: July 31, 2012.
Ron A. Otten,
Director, Office of Scientific Integrity (OSI),
Office of the Associate Director for Science
(OADS), Office of the Directors, Centers for
Disease Control and Prevention.
[FR Doc. 2012–19235 Filed 8–6–12; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day-12–12IG]

Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
requests, call the CDC Reports Clearance
Officer at 404–639–7570 or send an
email to [email protected]. Send written
comments to CDC Desk Officer, Office of
Management and Budget, Washington,
DC or by fax to (202) 395–5806.
Proposed Project
Targeted Surveillance and Biometric
Studies for Enhanced Evaluation of
Community Transformation Grants—
New—National Center for Chronic
Disease Prevention and Health
Promotion (NCCDPHP), Centers for
Disease Control and Prevention (CDC).

mstockstill on DSK4VPTVN1PROD with NOTICES

Number of
responses per
respondent

Number of
respondents

Types of respondent

Background and Brief Description
The Prevention and Public Health
Fund (PPHF) of the Patient Protection
and Affordable Care Act of 2010 (ACA)
provides an important opportunity for
states, counties, territories and tribes to
advance public health across the
lifespan and to reduce health
disparities. The PPHF authorizes
Community Transformation Grants
(CTG) for the implementation,

VerDate Mar<15>2010

16:52 Aug 06, 2012

Jkt 226001

evaluation, and dissemination of
evidence-based community preventive
health activities. The CTG Program
emphasizes five strategic directions: (1)
Tobacco-free living, (2) active lifestyles
and healthy eating, (3) high impact,
evidence-based clinical and other
preventive services, (4) social and
emotional well-being, and (5) healthy
and safe physical environments.
The CTG Program is administered by
the Centers for Disease Control and
Prevention (CDC), National Center for
Chronic Disease Prevention and Health
Promotion (NCCDPHP). As required by
Section 4201 of the ACA, CDC is
responsible for conducting a
comprehensive evaluation of the CTG
Program which includes assessment
over time of measures relating to each
of the five strategic directions.
CDC is requesting OMB approval to
collect information through two studies
needed for these assessments. One study
is a telephone and mailed survey (Adult
Targeted Surveillance Survey) of a
random sample of adults in 20 CTG
communities (1000 individuals per
community). Respondents will be asked
to provide information about household
practices and their personal behaviors
specific to the five strategic directions
(e.g., nutrition). Information from the
targeted surveillance surveys will be
compared with data from other local,
state or national surveillance systems to
monitor changes in relevant attitudes,
risk behaviors, and other behavioral
factors.
The second study for which OMB
approval is requested to conduct the
Youth and Adult Biometric Study
(YABS), in up to 8 CTG areas that are
implementing evidence-based strategies
to prevent exposure to secondhand
smoke and to improve nutrition and
physical activity among children and
adults (and are part of the targeted
surveillance study described above).
The YABS will examine the impact of
CTG strategies on biometric markers of
health status including weight, height
(i.e., body mass index or BMI), waist

PO 00000

Frm 00046

Fmt 4703

Sfmt 4703

circumference, secondhand smoke
exposure, and blood pressure. Each
adult respondent in the YABS will be
asked to participate in an in-home visit
with a trained interviewer, who will
collect biometric data about the
respondent such as height, weight,
saliva, blood pressure, etc. The adult
respondent will also be asked to provide
information about his or her activity
level over a one-week period. Objective
measures of activity will be collected
through use of an accelerometer, i.e., an
electronic meter worn next to the body.
In addition, the respondent will
maintain a hardcopy activity diary to
assist in interpreting the accelerometry
data. An adult YABS respondent who is
the parent or guardian of a child in the
household will be asked to allow one
child (age 3–17 years) to participate in
the youth component of the YABS. With
the child’s assent, similar biometric and
activity measures will be collected from
the child. If the child is between 3 and
11 years of age, the parent or guardian
will be asked to complete a Caregiver
Survey about the child’s behaviors. If
the child is between 12 and 17 years of
age, he or she will be asked to complete
a Youth Survey.
The estimated burden per response is
30 minutes for adults participating in
the first study, and up to an additional
60 minutes if the same adult agrees to
participate in the YABS study. The
estimated burden for youth between 12
and 17 years of age is 50 minutes, and
20 minutes for children aged 3 to 11
years. Caregivers for the younger
children will have an estimated burden
per response of 20 minutes to complete
the Caregiver Survey. The information
to be collected will allow CDC to
estimate the effect of all CTG
interventions on health behaviors and
health outcomes in adults and children
ages 3–17 years, and to estimate the
independent effect of school-based
interventions in youth. OMB approval is
requested for the first three years of the
five-year CTG project period.
Participation is voluntary and there are

E:\FR\FM\07AUN1.SGM

07AUN1